FiercePharma2h
2025 forecast: What can AstraZeneca's China probes teach other biopharma companies?
The second and more recent probe involves alleged smuggling of unapproved drugs—the Daiichi-partnered HER2 therapy Enhertu ...
FiercePharma21h
From AI and layoffs to supply chains and political unknowns, Deloitte outlines key areas for biopharma to watch in 2025
That’s according to the Deloitte U.S. Center for Health Solutions, which found in a recent survey of 150 C-suite executives ...
FiercePharma3d
With pair of trial wins in psoriatic arthritis, Bristol Myers Squibb looks to jump-start stagnant Sotyktu
Stagnant sales for Bristol Myers Squibb’s Sotyktu have raised questions about whether the tyrosine kinase 2 (TYK2) inhibitor ...
FiercePharma3d
FDA digs in its heels with another rejection for Lexicon's diabetes prospect Zynquista
Lexicon Pharmaceuticals has already thrown in the towel on its commercial efforts after a years-long uphill battle to get its ...
FiercePharma3d
Vertex snags FDA nod for once-daily cystic fibrosis triplet Alyftrek as switch from Trikafta kicks off
As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has ...
FiercePharma3d
Viatris says India plant hit with FDA warning letter, import ban on 11 products
Viatris disclosed that its manufacturing facility in Indore, India, was issued a warning letter from the FDA, which banned 11 ...
FiercePharma3d
Novo Nordisk wins hard-fought FDA approval for once-daily hemophilia med Alhemo
Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...
FiercePharma3d
Lonza to boost gelatin capsule capacity in India, China as it looks to shed the division
CDMO giant Lonza unveiled plans to expand hard gelatin capsule production capacity at plants in India and China a week after ...